An Update on FDA’s Contribution to COVID-19 Diagnostic Testing

Published date06 November 2020
Subject MatterEmergency Use Authorization (EUA),Over The Counter Drugs (OTC),Diagnostic Tests,FDA,Coronavirus/COVID-19,CMS,CLIA,Department of Health and Human Services (HHS),Virus Testing,Laboratory Developed Tests,Clinical Laboratory Testing,Life Sciences,Health Care Providers
AuthorJoanne Hawana
Law FirmMintz - Health Care Viewpoints

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT